Experienced in HER2 Negative Breast Cancer

Dr. Manmeet S. Ahluwalia

Hematology Oncology | Oncology | Hematology
Baptist Health Medical Group Oncology LLC
8900 N Kendall Dr, 
Miami, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in HER2 Negative Breast Cancer
Baptist Health Medical Group Oncology LLC
8900 N Kendall Dr, 
Miami, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Manmeet Ahluwalia is a Hematologist Oncology specialist and an Oncologist in Miami, Florida. Dr. Ahluwalia is rated as an Experienced provider by MediFind in the treatment of HER2 Negative Breast Cancer. His top areas of expertise are Brain Tumor, Glioblastoma, Astrocytoma, and Glioma. Dr. Ahluwalia is currently accepting new patients.

His clinical research consists of co-authoring 273 peer reviewed articles and participating in 27 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of HER2 Negative Breast Cancer.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in FL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO

Locations

BAPTIST HEALTH MEDICAL GROUP ONCOLOGY LLC
8900 N Kendall Dr, Miami, FL 33176

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

27 Clinical Trials

GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
GBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBM
Enrollment Status: Recruiting
Publish Date: September 09, 2025
Intervention Type: Drug, Radiation, Biological
Study Drugs: Temozolomide, Lomustine, Regorafenib, Paxalisib, VAL-083
Study Phase: Phase 2/Phase 3
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).
Enrollment Status: Completed
Publish Date: October 31, 2025
Intervention Type: Device, Other
Study Phase: Phase 3
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
A Phase II Study of the Safety and Efficacy of SVN53-67/M57-KLH (SurVaxM) in Survivin-Positive Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Montanide ISA 51 VG, Sargramostim, SVN53-67/M57-KLH Peptide Vaccine, Temozolomide
Study Phase: Phase 2
Phase I Study of Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Phase I Study of Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: September 30, 2025
Intervention Type: Drug, Radiation
Study Drugs: Ibrutinib, Temozolomide
Study Phase: Phase 1
Prospective Surgical Study on the Feasibility of Semi-Automated Tissue Collection, Stabilization, Preservation, and Site Transfer - Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue
Prospective Surgical Study on the Feasibility of Semi-Automated Tissue Collection, Stabilization, Preservation, and Site Transfer - Improving Understanding of Brain Tumors Through Preservation of Biologically Active Brain Tissue
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2025
Intervention Type: Device
Study Phase: Not Applicable
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: June 05, 2025
Intervention Type: Drug
Study Drug: Regorafenib
Study Phase: Phase 2
CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)
CA209-382 A Randomized Phase 2 Open Label Study of Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in Recurrent Glioblastoma (GBM)
Enrollment Status: Active_not_recruiting
Publish Date: February 28, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Bevacizumab
Study Phase: Phase 2
A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
A Prospective Phase II Trial of NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: February 17, 2025
Intervention Type: Biological, Device, Other
Study Phase: Phase 2
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Radiation, Biological, Other, Drug
Study Drugs: AdV-tk, Valacyclovir, Temozolomide, Nivolumab
Study Phase: Phase 1
A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
A Phase 1b/2 Study to Assess the Safety, Tolerability and Efficacy of BGB-290 in Combination With Radiation Therapy (RT) and/or Temozolomide (TMZ) in Subjects With First-line or Recurrent/Refractory Glioblastoma
Enrollment Status: Completed
Publish Date: February 04, 2025
Intervention Type: Drug, Radiation
Study Phase: Phase 1/Phase 2
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Procedure
Study Drugs: BGB-290 PARP Inhibitor, Temozolomide
Study Phase: Phase 1/Phase 2
Phase I Study of Ruxolitinib With Radiation and Temozolomide in Patients With Newly Diagnosed Grade III Gliomas and Glioblastoma
Phase I Study of Ruxolitinib With Radiation and Temozolomide in Patients With Newly Diagnosed Grade III Gliomas and Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 08, 2025
Intervention Type: Drug, Radiation
Study Drugs: Ruxolitinib, Temozolomide
Study Phase: Phase 1
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
Enrollment Status: Terminated
Publish Date: October 31, 2024
Intervention Type: Biological, Drug
Study Drugs: Encorafenib, Binimetinib
Study Phase: Phase 2
Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Phase II Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drugs: Pembrolizumab, SurVaxM, Sargramostim, Montanide ISA 51
Study Phase: Phase 2
Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Enrollment Status: Terminated
Publish Date: June 24, 2024
Intervention Type: Drug, Radiation
Study Drug: BAL101553
Study Phase: Phase 1
Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Newly Diagnosed Glioblastoma
Feasibility Study on Laser Interstitial Thermal Therapy Ablation for the Treatment of Newly Diagnosed Glioblastoma
Enrollment Status: Terminated
Publish Date: April 12, 2024
Intervention Type: Device, Drug
Study Phase: Phase 1
Phase 1 Trial of Osimertinib With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From EGFR Positive Non-Small-Cell Lung Cancer (NSCLC)
Phase 1 Trial of Osimertinib With Stereotactic Radiosurgery (SRS) in Patients With Brain Metastases From EGFR Positive Non-Small-Cell Lung Cancer (NSCLC)
Enrollment Status: Completed
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drug: Osimertinib
Study Phase: Phase 1
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
Enrollment Status: Completed
Publish Date: October 06, 2023
Intervention Type: Biological, Other
Study Drugs: Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Anti-CD137
Study Phase: Phase 1
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Enrollment Status: Terminated
Publish Date: October 06, 2023
Intervention Type: Drug
Study Drug: Regadenoson
Study Phase: Phase 1
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
Enrollment Status: Terminated
Publish Date: October 06, 2023
Intervention Type: Biological, Other
Study Drug: NT-I7
Study Phase: Phase 1
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed Glioblastoma
Enrollment Status: Completed
Publish Date: January 10, 2023
Intervention Type: Biological, Other, Drug
Study Drugs: Ipilimumab, Nivolumab, Temozolomide
Study Phase: Phase 1
Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma
Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 2
An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme
An International, Multi-Center, Randomized, Double Blind Placebo Controlled Phase II Study to Evaluate the Safety and Efficacy of Lucanthone Administered as an Adjunct to Radiation and Temozolomide for Primary Therapy of Glioblastoma Multiforme
Enrollment Status: Terminated
Publish Date: October 19, 2021
Intervention Type: Drug, Radiation
Study Phase: Phase 2
A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
A Phase 2, Multicenter Study of Tesevatinib Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: September 22, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid Neoplasm
Enrollment Status: Completed
Publish Date: December 10, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges
A Phase II, Multi-center, Open-label, Five-arm Study to Evaluate the Efficacy and Safety of Oral Ceritinib Treatment for Patients With ALK-positive Non-small Cell Lung Cancer (NSCLC) Metastatic to the Brain and/or to Leptomeninges
Enrollment Status: Completed
Publish Date: April 21, 2020
Intervention Type: Drug
Study Phase: Phase 2
Phase II Study of TRC102 in Combination With Temozolomide for Recurrent Glioblastoma
Phase II Study of TRC102 in Combination With Temozolomide for Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: April 04, 2019
Intervention Type: Drug, Other
Study Phase: Phase 2
View 26 Less Clinical Trials

271 Total Publications

Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Prior anti-PD-1/L1 Exposure (NCI/SWOG S1609).
Outcomes of Patients with Rare Cancers Treated with Combination Immune Checkpoint Inhibitors With and Without Prior anti-PD-1/L1 Exposure (NCI/SWOG S1609).
Journal: JCO oncology advances
Published: December 08, 2025
Similar Doctors
Advanced in HER2 Negative Breast Cancer
Dr. Elizabeth R. Stone
Oncology | Hematology
Advanced in HER2 Negative Breast Cancer
Dr. Elizabeth R. Stone
Oncology | Hematology

Cleveland Clinic Florida (A Nonprofit Corporation)

3100 Weston Rd, 
Weston, FL 
 (27.6 miles away)
954-659-5000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Elizabeth Stone is an Oncologist and a Hematologist in Weston, Florida. Dr. Stone is rated as a Distinguished provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and HER-2 Positive Breast Cancer. Dr. Stone is currently accepting new patients.

Experienced in HER2 Negative Breast Cancer
Dr. Reshma L. Mahtani
Oncology | Hematology Oncology | Hematology
Experienced in HER2 Negative Breast Cancer
Dr. Reshma L. Mahtani
Oncology | Hematology Oncology | Hematology

Baptist Health Medical Group Oncology LLC

8900 N Kendall Dr, 
Miami, FL 
 (0.1 miles away)
786-596-2000
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Reshma Mahtani is an Oncologist and a Hematologist Oncology provider in Miami, Florida. Dr. Mahtani is rated as a Distinguished provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Breast Cancer, Febrile Neutropenia, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Mahtani is currently accepting new patients.

Advanced in HER2 Negative Breast Cancer
Dr. Adria Suarez-Mora
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Advanced in HER2 Negative Breast Cancer
Dr. Adria Suarez-Mora
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Cleveland Clinic Florida (A Nonprofit Corporation)

2950 Cleveland Clinic Blvd, 
Weston, FL 
 (27.6 miles away)
954-659-5000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Adria Suarez-Mora is a Gynecologic Oncologist and an Oncologist in Weston, Florida. Dr. Suarez-Mora is rated as an Advanced provider by MediFind in the treatment of HER2 Negative Breast Cancer. Her top areas of expertise are Neonatal Ovarian Cyst, Ovarian Cysts, Hydrocele, DICER1 Syndrome, and Intrauterine Device Insertion. Dr. Suarez-Mora is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ahluwalia's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 10 Distinguished Conditions
View All 8 Advanced Conditions
View All 16 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile